je.st
news
Onyx Snubbing Amgen Paves Way for 89% Premium: Real M&A
2013-07-03 06:25:34| Biotech - Topix.net
Onyx Pharmaceuticals Inc. , which surged more than 50 percent after rejecting a bid from Amgen Inc., is betting that potential suitors from Bayer AG to Bristol-Myers Squibb Co.
Tags: real
ma
premium
onyx
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||